Patient outcomes with ribociclib or abemaciclib for early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with stage II or III breast cancer.
- Your breast cancer type is HR-positive (hormone receptor positive) and HER2-negative.
- You have started treatment with ribociclib or abemaciclib plus hormone therapy within the last 14 days.
- You have not had breast cancer come back after earlier treatment.
- You are not currently in another clinical trial taking experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests whether a newer targeted therapy (dalpiciclib) causes fewer side effects than two similar drugs (abemaciclib and ribociclib) in people with early-stage, hormone receptor-positive, HER2-negative breast cancer after surgery. The goal is to find a better-tolerated treatment to reduce the risk of cancer returning.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.